Revolution Medicines formed a multi-year collaboration with AI-driven drug discovery company Iambic Therapeutics to advance oncology target discovery using AI models. Iambic will train its NeuralPLexer and PropANE AI platforms on Revolution's proprietary molecular libraries, enabling rapid protein-ligand interaction predictions and lead compound optimization. The partnership includes up to $25 million in payments and represents a growing trend integrating AI for high-throughput pharmaceutical research and precision medicine.